Pages that link to "Q46954005"

The following pages link to Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice (Q46954005):

Displaying 38 items.

• Drug efflux transporters and multidrug resistance in acute leukemia: therapeutic impact and novel approaches to mediation (Q26824355) (← links)
• Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities (Q26828930) (← links)
• A unique carrier for delivery of therapeutic compounds beyond the blood-brain barrier (Q28472987) (← links)
• Codelivery of chemotherapeutics via crosslinked multilamellar liposomal vesicles to overcome multidrug resistance in tumor (Q28543911) (← links)
• Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy (Q33859472) (← links)
• Solid phase synthesis of tariquidar-related modulators of ABC transporters preferring breast cancer resistance protein (ABCG2) (Q33899488) (← links)
• Activation of PKC isoform beta(I) at the blood-brain barrier rapidly decreases P-glycoprotein activity and enhances drug delivery to the brain (Q34171206) (← links)
• Rapid loss of blood-brain barrier P-glycoprotein activity through transporter internalization demonstrated using a novel in situ proteolysis protection assay (Q34171352) (← links)
• Reversal of MRP7 (ABCC10)-mediated multidrug resistance by tariquidar (Q34581006) (← links)
• Benzanilide-Biphenyl Replacement: A Bioisosteric Approach to Quinoline Carboxamide-Type ABCG2 Modulators (Q35181940) (← links)
• Breast Cancer Resistance Protein and P-Glycoprotein in Brain Cancer: Two Gatekeepers Team Up (Q35720625) (← links)
• Drug resistance in glioblastoma: a mini review (Q35899534) (← links)
• Brain distribution and bioavailability of elacridar after different routes of administration in the mouse (Q36105340) (← links)
• Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib. (Q36613936) (← links)
• Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system (Q36717122) (← links)
• Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor (Q36949086) (← links)
• Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain (Q37331814) (← links)
• Drug interactions at the blood-brain barrier: fact or fantasy? (Q37362486) (← links)
• The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. (Q37438909) (← links)
• A review of multifunctional nanoemulsion systems to overcome oral and CNS drug delivery barriers (Q37798553) (← links)
• Novel and Emerging Strategies in Drug Delivery for Overcoming the Blood–Brain Barrier (Q37855817) (← links)
• Transporter-Mediated Drug Uptake and Efflux: Important Determinants of Adverse Drug Reactions (Q37862576) (← links)
• Tau as a Therapeutic Target for Alzheimers Disease (Q37890451) (← links)
• Shuttle-mediated drug delivery to the brain (Q37896550) (← links)
• Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit? (Q38055067) (← links)
• ABC transporters at the blood-brain barrier (Q38783122) (← links)
• Quinoline carboxamide-type ABCG2 modulators: indole and quinoline moieties as anilide replacements (Q39095577) (← links)
• Nanoformulations for combination or cascade anticancer therapy. (Q39380111) (← links)
• Elacridar, a third-generation ABCB1 inhibitor, overcomes resistance to docetaxel in non-small cell lung cancer. (Q41676866) (← links)
• Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat. (Q42476216) (← links)
• Increasing oxime efficacy by blood–brain barrier modulation (Q42733728) (← links)
• Evaluation of limiting brain penetration related to P-glycoprotein and breast cancer resistance protein using [(11)C]GF120918 by PET in mice (Q48243022) (← links)
• Evidence That P-glycoprotein Inhibitor (Elacridar)-Loaded Nanocarriers Improve Epidermal Targeting of an Anticancer Drug via Absorptive Cutaneous Transporters Inhibition (Q48653951) (← links)
• Validation of a liquid chromatographic method for the pharmaceutical quality control of products containing elacridar (Q49179365) (← links)
• Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells. (Q49888021) (← links)
• Retina compatible interactions and effective modulation of blood ocular barrier P-gp activity by third-generation inhibitors improves ocular penetration of loperamide. (Q53693173) (← links)
• Application of the Tumor Site Recognizable and Dual-Responsive Nanoparticles for Combinational Treatment of the Drug-Resistant Colorectal Cancer (Q90676304) (← links)
• Codelivery of doxorubicin and elacridar to target both liver cancer cells and stem cells by polylactide-co-glycolide/d-alpha-tocopherol polyethylene glycol 1000 succinate nanoparticles (Q93377757) (← links)